Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma

Anticancer Research

Volumn 30, Issue 9, 2010, Pages 3709-3714

  Coosemans, Ann ^a   Wölfl, Matthias ^b   Berneman, Zwi N ^c   Van Tendeloo, Viggo ^c   Vergote, Ignace ^a   Amant, Frédéric ^a   Van Gool, Stefaan W ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

DC; Endometrial carcinoma; Immunotherapy; WT1

Indexed keywords

CANCER VACCINE; CARBOPLATIN; DENDRITIC CELL VACCINE; DOXORUBICIN; HLA A2 ANTIGEN; MEDROXYPROGESTERONE; MESSENGER RNA; PACLITAXEL; WT1 PROTEIN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BRAIN METASTASIS; CANCER GROWTH; CANCER RECURRENCE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; ENDOMETRIUM CARCINOMA; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; KARNOFSKY PERFORMANCE STATUS; LAPAROSCOPY; MULTIPLE CYCLE TREATMENT; PERITONEUM METASTASIS; PRIORITY JOURNAL; QUALITY OF LIFE; T LYMPHOCYTE; CANCER STAGING; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENDOMETRIAL NEOPLASMS; IMMUNOLOGY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROCEDURES;

CANCER VACCINES; DENDRITIC CELLS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOTHERAPY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC; WT1 PROTEINS;

EID: 77958527547     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Boruta DM, Gehrig PA, Nickles Fader A and Olawaiye AB: Managment of women with uterine papillary serous cancer: a society of gynecologic oncology (SGO) review. Gynecol Oncol 115: 142-153, 2009.
2. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E and Vergote I: Endometrial cancer. Lancet 366: 491-505, 2005.
3. Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, Kawano K, Kuwae Y, Yamauchi A, Okumura M, Kitamura Y, Oka Y, Kawase I, Sugiyama H and Aozasa K: Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 19: 804-814, 2006.
4. Yang L, Han Y, Suarez SF and Minden MD: A tumor suppressor and oncogene: the WT1 story. Leukemia 21: 868-876, 2007.
5. Coosemans A, Moerman P, Verbist L, Maes W, Neven P, Vergote I, Van Gool SW and Amant F: Wilms' tumor gene 1 (WT1) in endometrial carcinoma. Gynecol Oncol 111: 502-508, 2008.
6. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM and Matrisian LM: The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research. Clin Cancer Res 15: 5323-5337, 2009.
7. Iiyama T, Udaka K, Takeda S, Takeuchi T, Adachi YC, Ohtsuki Y, Tsuboi A, Nakatsuka S, Elisseeva OA, Oji Y, Kawakami M, Nakajima H, Nishida S, Shirakata T, Oka Y, Shuin T and Sugiyama H: WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol 51: 519-530, 2007.
8. Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T, Kagawa N, Hashimoto N, Maruno M, Elisseeva OA, Shirakata T, Kawakami M, Oji Y, Nishida S, Ohno S, Kawase I, Hatazawa J, Nakatsuka S, Aozasa K, Morita S, Sakamoto J, Sugiyama H and Yoshimine T: Phase II clinical trial of Wilms' tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 108: 963-971, 2008.
9. Morita S, Oka Y, Tsuboi A, Kawakami M, Maruno M, Izumoto S, Osaki T, Taguchi T, Ueda T, Myoui A, Nishida S, Shirakata T, Ohno S, Oji Y, Aozasa K, Hatazawa J, Udaka K, Yoshikawa H, Yoshimine T, Noguchi S, Kawase I, Nakatsuka S, Sugiyama H and Sakamoto J: A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Jpn J Clin Oncol 36: 231-236, 2006.
10. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, Elisseeva OA, Oji Y, Kawakami M, Ikegame K, Hosen N, Yoshihara S, Wu F, Fujiki F, Murakami M, Masuda T, Nishida S, Shirakata T, Nakatsuka S, Sasaki A, Udaka K, Dohy H, Aozasa K, Noguchi S, Kawase I and Sugiyama H: Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 101: 13885-13890, 2004.
11. Tsuboi A, Oka Y, Osaki T, Kumagai T, Tachibana I, Hayashi S, Murakami M, Nakajima H, Elisseeva OA, Fei W, Masuda T, Yasukawa M, Oji Y, Kawakami M, Hosen N, Ikegame K, Yoshihara S, Udaka K, Nakatsuka S, Aozasa K, Kawase I and Sugiyama H:WT1 peptide-based immunotherapy for patients with lung cancer report of two cases. Microbiol Immunol 48: 175-184, 2004.
12. Gilboa E and Vieweg J: Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 199: 251-263, 2004. (Pubitemid 38744521)
13. Aarntzen EH, Figdor CG, Adema GJ, Punt CJ and de Vries IJ: Dendritic cell vaccination and immune monitoring. Cancer Immunol Immunother 57: 1559-1568, 2008.
14. Erdmann M, Dorrie J, Schaft N, Strasser E, Hendelmeier M, Kämpgen E, Schuler G and Schuler-Thurner B: Effective clinical-scale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and final antigen loading using peptides or RNA transfection. J Immunother 30: 663-674, 2007.
15. Michiels A, Tuyaerts S, Bonehill A, Corthals J, Breckpot K, Heirman C, Van Meirvenne S, Dullaers M, Allard S, Brasseur F, van der Bruggen P and Thielemans K: Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Ther 12: 772-782, 2005.
16. Van Tendeloo VF, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C, Van Bockstaele DR and Berneman ZN: Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 98: 49-56, 2001.
17. Van Tendeloo VF, Ponsaerts P and Berneman ZN: mRNA-based gene transfer as a tool for gene and cell therapy. Curr Opin Mol Ther 9: 423-431, 2007.
18. Van Driessche A, Van de Velde AL, Nijs G, Braeckman T, Stein B, De Vries JM, Berneman ZN and Van Tendeloo VF: Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy 11: 653-668, 2009.
19. De Vleeschouwer S, Arredouani M, Adé M, Cadot P, Vermassen E, Ceuppens JL and Van Gool SW: Uptake and presentation of malignant glioma tumor cell lysates by monocytes-derived dendritic cells. Cancer Immunol Immunother 54: 372-382, 2005.
20. De Vleeschouwer S, Spencer Lopes I, Ceuppens JL and Van Gool SW: Persistent IL-10 production is required for glioma growth suppressive activity by Th-1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells. J Neurooncol 84: 131-140, 2007.
21. Maes W, Rosas GG, Verbinnen B, Boon L, De Vleeschouwer S, Ceuppens JL and Van Gool SW: DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro Oncol 11: 529-542, 2009.
22. De Vleeschouwer S, Van Calenbergh F, Demaerel P, Flamen P, Rutkowski S, Kaempgen E, Wolff JE, Plets C, Sciot R and Van Gool SW: Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report. J Neurosurg 100: 492-497, 2004.
23. Rutkowski S, De Vleeschouwer S, Kaempgen E, Wolff JE, Kühl J, Demaerel P, Warmuth-Metz M, Flamen P, Van Calenbergh F, Plets C, Sörensen N, Opitz A and Van Gool SW: Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed Malignant glioma, a feasibility study. Br J Cancer 91: 1656-1662, 2004.
24. De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, Sciot R, Wilms' G, Demaerel P, Warmuth-Metz M, Soerensen N, Wolff JE, Wagner S, Kaempgen E and Van Gool SW: Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14: 3098-3104, 2008.
25. Van Gool S, Maes W, Ardon H, Verschuere T, Van Cauter S and De Vleeschouwer S: Dendritic cell therapy of high grade gliomas. Brain Pathol 19: 694-712, 2009.
26. Coosemans A, Nik SA, Caluwaerts S, Lambin S, Verbist G, Van Bree R, Schelfhout V, de Jonge E, Dalle I, Jacomen G, Cassiman JJ, Moerman P, Vergote I and Amant F: Upregulation of Wilms' tumour gene 1 (WT1) in uterine sarcomas. Eur J Cancer 43: 1630-1637, 2007.
27. Ohno S, Kyo S, Moyojo S, Dohi S, Ishizaki J, Miyamoto K, Morita S, Sakamoto J, Enomoto T, Kimura T, Oka Y, Tsuboi A, Sugiyama H and Inoue M: Wilms' tumor 1 (WT1) peptide immunotherapy for gynaecological malignancy. Anticancer Research 29: 4779-4784, 2009.
28. Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, Hofmann WK, Uharek L, Thiel E and Scheibenbogen C: A clinical and immunological phase 2 trial of Wilms' tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 113: 6541-6548, 2009.
29. Hernando JJ, Park T-W, Fisher H-P, Zivanovic O, Braun M, Pölcher M, Grünn U, Leutner C, Pötzsch B and Kuhn W: Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-α for relapsed metastatic ovarian cancer. Lancet Oncol 8: 451-454, 2007.
30. Steinman RM and Banchereau J: Taking dendritic cells into medicine. Nature 449: 419-426, 2007
31. GehrigPA and Bae-Jump VL: Promising novel therapies for the treatment of endometrial cancer. Gynecol Oncol 116: 187-194, 2010.